Cinacalcet hydrochloride is a Small Molecule owned by Takeda Pharmaceutical, and is involved in 48 clinical trials, of which 47 were completed, and 1 is ongoing.
Cinacalcet is calcium sensing receptor agonist. The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of parathyroid hormone (PTH) synthesis and secretion. Hyperparathyroidism with CKD is associated with increased PTH and derangements in calcium and phosphorus metabolism. The drug candidate directly lowers PTH levels by increasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
The revenue for Cinacalcet hydrochloride is expected to reach a total of $751m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cinacalcet hydrochloride NPV Report.
Cinacalcet hydrochloride was originated by Shire-NPS Pharmaceuticals and is currently owned by Takeda Pharmaceutical. Amgen and Kyowa Kirin are the other companies associated in development or marketing of Cinacalcet hydrochloride.
Cinacalcet hydrochloride Overview
Cinacalcet hydrochloride (Sensipar/ Mimpara/ Regpara) is a calcimimetic agent that mimics the action of calcium in the body. It is formulated as tablets and film coated tablets for oral administration. Sensipar is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with end-stage kidney failure, reduction of hypercalcaemia. Sensipar is indicated for the treatment of hypercalcemia in adult patients with Parathyroid Carcinoma. Sensipar is indicated for the treatment of hypercalcemia in adult patients with primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. Mimpara also indicated for the treatment of secondary hyperparathyroidism (HPT) in children aged three years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy.
Cinacalcet hydrochloride was under development for the treatment of secondary hyperparathyroidism in pediatric patients with chronic kidney disease receiving dialysis in the U.S.
Kyowa Kirin Overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.
Quick View – Cinacalcet hydrochloride
|Highest Development Stage|